ANVISA, the Brazilian Health Regulatory Agency, has approved Beta Drugs Limited's state-of-the-art oncology production factory in Kharuni Lodhi Majra Road, Village Nandpur, Baddi, Himachal Pradesh, India.

ANVISA was granted to the company for its oral solids (tablets and capsules) and injectables (liquid and lyophilised) formulations. As a result, Beta Drugs now possesses the Pharmaceutical Inspection Co-operation Scheme (PICS) certification.

Following this, the company will have access to various new opportunities in the Brazilian market (the world's 12th largest pharma market) as well as other important potential markets such as Thailand, Malaysia, Singapore, Iran, Mexico, Vietnam, Ukraine, and South Africa. It has already identified potential partners in these countries, and product registrations for injectables and oral formulations will follow in the coming months.

Beta also anticipates a Eurasian Economic Union (EAEU) assessment in May. The organisation is dedicated to helping people all around the world with new and effective healthcare solutions. The ANVISA accreditation exemplifies Beta's 'quality first' work philosophy.

The global oncology industry is expanding fast, and Beta Drugs Ltd is well-positioned to address the growing need for effective cancer therapies in India and other worldwide markets.